Vertex Ventures HC

Vertex Ventures HC investment thesis

Boundless Bio develops ecDNA-directed therapies (ecDTx) intended to transform the lives of patients with aggressive gene amplified cancers Previous Next Redona Therapeutics targets nucleic acid process and sensing enzymes to address challenging diseases including cancer Previous Next Palleon Pharmaceuticals targets the glycan-sensing checkpoints to unleash both innate and adaptive immune response to cancer Previous Next Matchpoint Therapeutics discovers precision covalent medicines to transform the treatment of immune diseases and other serious illnesses Previous Next Sonoma Biotherapeutics creates living cell therapies to restore the immune system back to its balanced and fully functioning state Previous Next Neuspera develops implantable medical device technology to improve lives of pati

Vertex Ventures HC team (5)

Partners and principals at Vertex Ventures HC:

• Christine Brennan — sweet spot $1.5M
• Sahil Chopra — sweet spot $1.5M
• Shawn Fu — sweet spot $1.5M
• Yoh-Chie LU — sweet spot $1.5M
• Jeff Schlosser — sweet spot $1.5M

Is Vertex Ventures HC a fit for your round?

Upload your pitch deck and see whether anyone at Vertex Ventures HC appears in your top matches.